Lenalidomide – A Brief Review of its Use in Myelodysplastic Syndromes
Keyword(s):
Myelodysplastic syndromes (MDS) are a heterogeneous group of blood diseases mainly affecting older people. Deletion of the long arm of chromosome 5 (del[5q]) is reported in approximately 10–15 % of all MDS cases. Lenalidomide is an immunomodulatory, anti-cytokine and anti-angiogenic agent, which leads to red blood cells transfusion independence in patients of lower risk MDS with del(5q). This review briefly describes role of lenalidomide in treatment of lower-risk MDS with del(5q) as well as non-del-5q MDS. Recent evidence also suggest a potential role of lenalidomide in combination with other agents for treatment of higher-risk MDS
Keyword(s):
Keyword(s):
2010 ◽
Vol 142
(1)
◽
pp. 2-7
◽
1991 ◽
pp. 285-300
◽
1974 ◽
Vol 29
(9-10)
◽
pp. 510-515
◽
1957 ◽
Vol 36
(6 Pt 1)
◽
pp. 833-843
◽
Keyword(s):